5-(2-Aminothiazol-5-ylthio)-2-methoxy-4-methylbenzoic acid

Catalog No. :
ACSTON350
CAS No. :
439578-97-9
Molecular Formula :
C12H12N2O3S2
Molecular Weight :
296.37

IUPAC Name:5-((2-aminothiazol-5-yl)thio)-2-methoxy-4-methylbenzoic acid

5-(2-Aminothiazol-5-ylthio)-2-methoxy-4-methylbenzoic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$252.00Login to see priceIn stockInquiry
250mg95%$417.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-(2-Aminothiazol-5-ylthio)-2-methoxy-4-methylbenzoic acid
IUPAC Name5-((2-aminothiazol-5-yl)thio)-2-methoxy-4-methylbenzoic acid
MDL No.MFCD19443226
Molecular FormulaC12H12N2O3S2
Molecular Weight296.37
SMILESO=C(O)C1=CC(SC2=CN=C(N)S2)=C(C)C=C1OC
InChI KeyPIFLMPUVILEPOT-UHFFFAOYSA-N
Synonym5-(2-aMinothiazol-5-ylthio)-2-Methoxy-4-Methylbenzoic acid;5-(2-Aminothiazol-5-yl)sulfanyl-2-methoxy-4-methylbenzoic acid;Benzoic acid, 5-[(2-amino-5-thiazolyl)thio]-2-methoxy-4-methyl-;RMA-376;5-[(2-amino-1,3-thiazol-5-yl)sulfanyl]-2-methoxy-4-methylbenzoic acid
CAS No.439578-97-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACSTON350 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACSFNR960 route compound structure diagram
    ACSFNR960439579-12-1 In Stock
  2. Plus
  3. ACGLFX394 route compound structure diagram
    ACGLFX394133692-18-9 In Stock
  4. Then
  5. ACSTON350 route product structure diagram
    ACSTON350439578-97-9 In Stock
Inquiry

2. ACSTON350 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACSTON350 route product structure diagram
    ACSTON350439578-97-9 In Stock
Inquiry

Comments (0)